表紙:肺動脈性肺高血圧症(PAH) - 市場考察、疫学、市場予測(2032年)
市場調査レポート
商品コード
1179462

肺動脈性肺高血圧症(PAH) - 市場考察、疫学、市場予測(2032年)

Pulmonary Arterial Hypertension - Market Insight, Epidemiology And Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 242 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
肺動脈性肺高血圧症(PAH) - 市場考察、疫学、市場予測(2032年)
出版日: 2022年12月01日
発行: DelveInsight
ページ情報: 英文 242 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)の肺動脈性肺高血圧症(PAH)の市場規模は、2021年に約48億7,100万米ドルであり、2032年までにさらなる成長が予測されています。

当レポートでは、肺動脈性肺高血圧症(PAH)の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 PAH市場の概要

  • PAHの市場シェア分布(2019年)
  • PAHの市場シェア分布(2032年)

第4章 PAHの疫学と市場の調査手法

第5章 PAHのエグゼクティブサマリー

第6章 主な出来事

第7章 疾患の背景と概要

  • PAHのイントロダクション
  • 兆候と症状
  • PAHの分類
  • 病因
  • 危険因子
  • 病態生理学
  • 診断
  • 管理と治療
  • 治療ガイドライン

第8章 疫学と患者数

  • 主な調査結果
  • 前提条件と理論的根拠:主要7市場
  • 主要7市場のPAHの総症例数
  • 主要7市場のPAHの総診断数
  • 米国
  • 欧州4ヶ国・英国
  • 日本

第9章 ペイシェントジャーニー

第10章 上市済み薬品

第11章 新薬

第12章 PAH:市場の分析

  • 主な調査結果
  • 主な市場の予測の前提条件
  • 市場の見通し
  • 属性分析
  • 主要7市場のPAHの市場規模
  • 主要7市場のPAHの市場規模:治療法別
  • 米国のPAHの市場規模
    • PAHの総市場規模
    • PAHの市場規模:治療法別
  • 欧州4ヶ国・英国のPAHの市場規模
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本のPAHの市場規模

第13章 主なオピニオンリーダーの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場参入と償還

  • 米国
  • 欧州4ヶ国・英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of PAH Market and Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: Clinical features
  • Table 4: Clinical Features
  • Table 5: Total Prevalent Cases of PAH in the 7MM (2019-2032)
  • Table 6: Total Diagnosed Cases of PAH in the 7MM (2019-2032)
  • Table 7: Total Prevalent Cases of PAH in the US (2019-2032)
  • Table 8: Total Diagnosed Cases of PAH in the US (2019-2032)
  • Table 9: Age-specific Cases of PAH in the US (2019-2032)
  • Table 10: Class-specific Cases of PAH in the US (2019-2032)
  • Table 11: Gender-specific Cases of PAH in the US (2019-2032)
  • Table 12: Subtype-specific Cases of PAH in the US (2019-2032)
  • Table 13: Total Prevalent Cases of PAH in EU4 and the UK (2019-2032)
  • Table 14: Total Diagnosed Cases of PAH in EU4 and the UK (2019-2032)
  • Table 15: Age-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Table 16: Class-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Table 17: Gender-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Table 18: Subtype-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Table 19: Total Prevalent Cases of PAH in Germany (2019-2032)
  • Table 20: Total Diagnosed Cases of PAH in Germany (2019-2032)
  • Table 21: Age-specific Cases of PAH in Germany (2019-2032)
  • Table 22: Class-specific Cases of PAH in Germany (2019-2032)
  • Table 23: Gender-specific Cases of PAH in Germany (2019-2032)
  • Table 24: Subtype-specific Cases of PAH in Germany(2019-2032)
  • Table 25: Total Prevalent Cases of PAH in France (2019-2032)
  • Table 26: Total Diagnosed Cases of PAH in France (2019-2032)
  • Table 27: Age-specific Cases of PAH in France (2019-2032)
  • Table 28: Class-specific Cases of PAH in France (2019-2032)
  • Table 29: Gender-specific Cases of PAH in France (2019-2032)
  • Table 30: Subtype-specific Cases of PAH in France (2019-2032)
  • Table 31: Total Prevalent Cases of PAH in Italy (2019-2032)
  • Table 32: Total Diagnosed Cases of PAH in Italy (2019-2032)
  • Table 33: Age-specific Cases of PAH in Italy (2019-2032)
  • Table 34: Class-specific Cases of PAH in Italy (2019-2032)
  • Table 35: Gender-specific Cases of PAH in Italy (2019-2032)
  • Table 36: Subtype-specific Cases of PAH in Italy (2019-2032)
  • Table 37: Total Prevalent Cases of PAH in Spain (2019-2032)
  • Table 38: Total Diagnosed Cases of PAH in Spain (2019-2032)
  • Table 39: Age-specific Cases of PAH in Spain (2019-2032)
  • Table 40: Class-specific Cases of PAH in Spain (2019-2032)
  • Table 41: Gender-specific Cases of PAH in Spain (2019-2032)
  • Table 42: Subtype-specific Cases of PAH in Spain (2019-2032)
  • Table 43: Total Prevalent Cases of PAH in the UK (2019-2032)
  • Table 44: Total Diagnosed Cases of PAH in the UK (2019-2032)
  • Table 45: Age-specific Cases of PAH in the UK (2019-2032)
  • Table 46: Class-specific Cases of PAH in the UK (2019-2032)
  • Table 47: Gender-specific Cases of PAH in the UK (2019-2032)
  • Table 48: Subtype-specific Cases of PAH in the UK (2019-2032)
  • Table 49: Total Prevalent Cases of PAH in Japan (2019-2032)
  • Table 50: Total Diagnosed Cases of PAH in Japan (2019-2032)
  • Table 51: Age-specific Cases of PAH in Japan (2019-2032)
  • Table 52: Class-specific Cases of PAH in Japan (2019-2032)
  • Table 53: Gender-specific Cases of PAH in Japan (2019-2032)
  • Table 54: Subtype-specific Cases of PAH in Japan (2019-2032)
  • Table 55: Comparison of Marketed Drugs
  • Table 56: UPTRAVI (selexipag), Clinical Trial Description, 2022
  • Table 57: TYVASO DPI, Clinical Trial Description, 2022
  • Table 58: ORENITRAM (treprostinil), Clinical Trial Description, 2022
  • Table 59: ADEMPAS (riociguat), Clinical Trial Description, 2022
  • Table 60: OPSUMIT (macitentan), Clinical Trial Description, 2022
  • Table 61: Comparison of Emerging Drugs Under Development
  • Table 62: Sotatercept (MK-7962), Clinical Trial Description, 2022
  • Table 63: Ralinepag, Clinical Trial Description, 2022
  • Table 64: YUTREPIA (treprostinil), Clinical Trial Description, 2022
  • Table 65: TNX-201, Clinical Trial Description, 2022
  • Table 66: RT234, Clinical Trial Description, 2022
  • Table 67: Seralutinib (GB002), Clinical Trial Description, 2022
  • Table 68: L606, Clinical Trial Description, 2022
  • Table 69: MK-5475, Clinical Trial Description, 2022
  • Table 70: AV-101, Clinical Trial Description, 2022
  • Table 71: Treprostinil Palmitil, Clinical Trial Description, 2022
  • Table 72: LTP001, Clinical Trial Description, 2022
  • Table 73: Oral Ifetroban, Clinical Trial Description, 2022
  • Table 74: Rodatristat Ethyl, Clinical Trial Description, 2022
  • Table 75: CS1, Clinical Trial Description, 2022
  • Table 76: Olaparib, Clinical Trial Description, 2022
  • Table 77: PB1046, Clinical Trial Description, 2022
  • Table 78: Key Market Forecast Assumptions for Sotatercept (MK-7962)
  • Table 79: Key Market Forecast Assumptions for ralinepag
  • Table 80: Key Market Forecast Assumptions for RT234 (vardenafil)
  • Table 81: Key Market Forecast Assumptions for seralutinib (GB002)
  • Table 82: Key Market Forecast Assumptions for YUTREPIA (inhaled treprostinil)
  • Table 83: Key Market Forecast Assumptions for TNX-201
  • Table 84: Market Size of PAH in the 7MM, in USD million (2019-2032)
  • Table 85: Market Size of PAH by Therapies in the 7MM, in USD million (2019-2032)
  • Table 86: Market Size of PAH in the US, in USD million (2019-2032)
  • Table 87: Market Size of PAH by Therapies in the US, in USD million (2019-2032)
  • Table 88: Market Size of PAH in EU4 and the UK, in USD million (2019-2032)
  • Table 89: Market Size of PAH in Germany, in USD million (2019-2032)
  • Table 90: Market Size of PAH by Therapies in Germany, in USD million (2019-2032)
  • Table 91: Market Size of PAH in France, in USD million (2019-2032)
  • Table 92: Market Size of PAH by Therapies in France, in USD million (2019-2032)
  • Table 93: Market Size of PAH in Italy, in USD million (2019-2032)
  • Table 94: Market Size of PAH by Therapies in Italy, in USD million (2019-2032)
  • Table 95: Market Size of PAH in Spain, in USD million (2019-2032)
  • Table 96: Market Size of PAH by Therapies in Spain, in USD million (2019-2032)
  • Table 97: Market Size of PAH in the UK, in USD million (2019-2032)
  • Table 98: Market Size of PAH by Therapies in the UK, in USD million (2019-2032)
  • Table 99: Market Size of PAH by Therapies in EU4 and the UK, in USD million (2019-2032)
  • Table 100: Market Size of PAH in Japan, in USD million (2019-2032)
  • Table 101: Market Size of PAH by Therapies in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: Symptoms of PAH
  • Figure 2: Classification of PAH
  • Figure 3: Functional Classification of PAH
  • Figure 4: Risk Factors of PAH
  • Figure 5: Pathophysiology of PAH
  • Figure 6: Pathophysiology of PAH
  • Figure 7: Diagnostic algorithm for PAH
  • Figure 8: Treatment Options for PAH
  • Figure 9: Treatment Algorithm for PAH
  • Figure 10: Total Prevalent Cases of PAH in the 7MM (2019-2032)
  • Figure 11: Total Diagnosed Cases of PAH in the 7MM (2019-2032)
  • Figure 12: Total Prevalent Cases of PAH in the US (2019-2032)
  • Figure 13: Total Diagnosed Cases of PAH in the US (2019-2032)
  • Figure 14: Age-specific Cases of PAH in the US (2019-2032)
  • Figure 15: Class-specific Cases of PAH in the US (2019-2032)
  • Figure 16: Gender-specific Cases of PAH in the US (2019-2032)
  • Figure 17: Subtype-specific Cases of PAH in the US (2019-2032)
  • Figure 18: Total Prevalent Cases of PAH in EU4 and the UK (2019-2032)
  • Figure 19: Total Diagnosed Cases of PAH in EU4 and the UK (2019-2032)
  • Figure 20: Age-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Figure 21: Class-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Figure 22: Gender-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Figure 23: Subtype-specific Cases of PAH in EU4 and the UK (2019-2032)
  • Figure 24: Total Prevalent Cases of PAH in Germany (2019-2032)
  • Figure 25: Total Diagnosed Cases of PAH in Germany (2019-2032)
  • Figure 26: Age-specific Cases of PAH in Germany (2019-2032)
  • Figure 27: Class-specific Cases of PAH in Germany (2019-2032)
  • Figure 28: Gender-specific Cases of PAH in Germany (2019-2032)
  • Figure 29: Subtype-specific Cases of PAH in Germany(2019-2032)
  • Figure 30: Total Prevalent Cases of PAH in France (2019-2032)
  • Figure 31: Total Diagnosed Cases of PAH in France (2019-2032)
  • Figure 32: Age-specific Cases of PAH in France (2019-2032)
  • Figure 33: Class-specific Cases of PAH in France (2019-2032)
  • Figure 34: Gender-specific Cases of PAH in France (2019-2032)
  • Figure 35: Subtype-specific Cases of PAH in France (2019-2032)
  • Figure 36: Total Prevalent Cases of PAH in Italy (2019-2032)
  • Figure 37: Total Diagnosed Cases of PAH in Italy (2019-2032)
  • Figure 38: Age-specific Cases of PAH in Italy (2019-2032)
  • Figure 39: Class-specific Cases of PAH in Italy (2019-2032)
  • Figure 40: Gender-specific Cases of PAH in Italy (2019-2032)
  • Figure 41: Subtype-specific Cases of PAH in Italy (2019-2032)
  • Figure 42: Total Prevalent Cases of PAH in Spain (2019-2032)
  • Figure 43: Total Diagnosed Cases of PAH in Spain (2019-2032)
  • Figure 44: Age-specific Cases of PAH in Spain (2019-2032)
  • Figure 45: Class-specific Cases of PAH in Spain (2019-2032)
  • Figure 46: Gender-specific Cases of PAH in Spain (2019-2032)
  • Figure 47: Subtype-specific Cases of PAH in Spain (2019-2032)
  • Figure 48: Total Prevalent Cases of PAH in the UK (2019-2032)
  • Figure 49: Total Diagnosed Cases of PAH in the UK (2019-2032)
  • Figure 50: Age-specific Cases of PAH in the UK (2019-2032)
  • Figure 51: Class-specific Cases of PAH in the UK (2019-2032)
  • Figure 52: Gender-specific Cases of PAH in the UK (2019-2032)
  • Figure 53: Subtype-specific Cases of PAH in the UK (2019-2032)
  • Figure 54: Total Prevalent Cases of PAH in Japan (2019-2032)
  • Figure 55: Total Diagnosed Cases of PAH in Japan (2019-2032)
  • Figure 56: Age-specific Cases of PAH in Japan (2019-2032)
  • Figure 57: Class-specific Cases of PAH in Japan (2019-2032)
  • Figure 58: Gender-specific Cases of PAH in Japan (2019-2032)
  • Figure 59: Subtype-specific Cases of PAH in Japan (2019-2032)
  • Figure 60: Patient Journey
  • Figure 61: Market Size of PAH in the 7MM, in USD million (2019-2032)
  • Figure 62: Market Size of PAH by Therapies in the 7MM, in USD million (2019-2032)
  • Figure 63: Market Size of PAH in the US, in USD million (2019-2032)
  • Figure 64: Market Size of PAH by Therapies in the US, in USD million (2019-2032)
  • Figure 65: Market Size of PAH in EU4 and the UK, in USD million (2019-2032)
  • Figure 66: Market Size of PAH in Germany, in USD million (2019-2032)
  • Figure 67: Market Size of PAH by Therapies in Germany, in USD million (2019-2032)
  • Figure 68: Market Size of PAH in France, in USD million (2019-2032)
  • Figure 69: Market Size of PAH by Therapies in France, in USD million (2019-2032)
  • Figure 70: Market Size of PAH in Italy, in USD million (2019-2032)
  • Figure 71: Market Size of PAH by Therapies in Italy, in USD million (2019-2032)
  • Figure 72: Market Size of PAH in Spain, in USD million (2019-2032)
  • Figure 73: Market Size of PAH by Therapies in Spain, in USD million (2019-2032)
  • Figure 74: Market Size of PAH in the UK, in USD million (2019-2032)
  • Figure 75: Market Size of PAH by Therapies in the UK, in USD million (2019-2032)
  • Figure 76: Market Size of PAH by Therapies in EU4 and the UK, in USD million (2019-2032)
  • Figure 77: Market Size of PAH in Japan, in USD million (2019-2032)
  • Figure 78: Market Size of PAH by Therapies in Japan, in USD million (2019-2032)
  • Figure 79: Unmet Needs
  • Figure 80: Health Technology Assessment
  • Figure 81: Reimbursement Process in Germany
  • Figure 82: Reimbursement Process in France
  • Figure 83: Reimbursement Process in Italy
  • Figure 84: Reimbursement Process in Spain
  • Figure 85: Reimbursement Process in the United Kingdom
  • Figure 86: Reimbursement Process in Japan
目次
Product Code: DIMI0186

DelveInsight's 'Pulmonary Arterial Hypertension - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Pulmonary Arterial Hypertension market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 7MM Pulmonary Arterial Hypertension market size from 2019 to 2032. The Report also covers current Pulmonary Arterial Hypertension treatment practice, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2019-2032

Pulmonary Arterial Hypertension Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension Overview

Pulmonary Hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during exercise as measured by right heart catheterization. It is often characterized by a progressive and sustained increase in pulmonary vascular resistance (PVR) that eventually leads to right ventricular failure. It can be a life-threatening condition if untreated. The World Health Organization (WHO) has divided PH into five groups based on similarities in pathophysiology, clinical presentation, and therapeutic options. Of these PAH belongs to WHO Group 1.

PAH is a rare, progressive disorder characterized by hypertension in the pulmonary arteries for no apparent reason. It was defined by the 6th World Symposium on Pulmonary Hypertension (WSPH) as a resting mean pulmonary artery pressure (mPAP) of 20 mm Hg or greater, a normal end-expiratory pulmonary artery wedge pressure (PAWP) less than or equal to 15 mm Hg, and a PVR of greater than or equal to 3 Wood units. PAH is further classified by the WHO into the following types: idiopathic PAH (IPAH), heritable PAH (HPAH), drug and toxin-induced PAH, and PAH associated with other diseases and disorders. The associated conditions include cirrhosis, HIV, congenital heart disease, and connective tissue diseases like scleroderma among others.

The initial symptom includes severe shortness of breath following exertion, including excessive fatigue, weakness, chest pain, dizzy spells, and fainting episodes. Hemoptysis, hypotension, and hoarseness due to compression of a nerve in the chest by an enlarged pulmonary artery are also observed. In advanced stages, syncope, tachypnea, cyanosis, and hypertrophy resulting in diminished functioning of the right portion of the heart are observed, often leading to right heart failure.

The most common form of PAH is idiopathic, characterized by elevated vascular resistance and pulmonary vasculature blood vessel constriction. It is considered that molecular and genetic factors, which result in the hypertrophy of smooth muscle, endothelial cells, and adventitia, are the root causes of restricted flow via pulmonary arteries, as seen in PAH.

The exact cause of PAH is unknown but in HPAH, an autosomal dominant genetic condition, mutations in the BMPR2 gene are the most common cause. PAH leads to disruption in one or more of three key pathways: nitric oxide (NO), prostacyclin (PGI2), thromboxane A2 (TXA2), and endothelin-1 (ET-1) leading to vasoconstriction, increased smooth muscle cell formation, inflammation, and thrombosis. These imbalances contribute to changes in the blood vessels, which further impact the progression of this disease.

Pulmonary Arterial Hypertension Diagnosis

Symptoms usually go unnoticed and may be present for up to 2 or 3 years before a diagnosis is made, often leading to misdiagnosis or a delay in early-stage diagnosis. While the global guidelines for PAH promote cardiac catheterization as the gold standard for diagnosis, transthoracic echocardiography is the most prevalent method of diagnosis.

Electrocardiogram (ECG), chest radiography, pulmonary function tests, and blood tests are also done to determine PAH. With improvement in disease understanding, biomarker-based assay and genetic testing are also being done to ascertain PAH. The Six-Minute Walk Test (6MWT) is also a widely used test to determine a patient's activity tolerance and estimated 1-year mortality.

Continued in the report…..

Pulmonary Arterial Hypertension Treatment

Treatment of patients with PAH is based on a patient's vasoreactivity test and functional capacity as determined by the WHO functional capacity classification. The goal is to increase vasodilation of the pulmonary vasculature and decrease PAP to increase CO.

The systematic step-by-step approach to managing PAH starts with general supportive care and progresses to focused pharmacological therapies. Individuals with PAH who respond to a vasoreactivity test performed during their RHC are treated with calcium channel blockers (CCB) such as nifedipine, diltiazem, and amlodipine. Targeted monotherapy or combination treatments that combat the pathophysiology of the illness are the treatment choice for those who either do not meet the criteria for vasoreactivity testing or exhibit an insufficient response.

The current mainstay therapies that include PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analog, and agonists, for the treatment of PAH target the three major pathways, NO/cGMP, endothelin, and prostacyclin.

Continued in the report…..

Pulmonary Arterial Hypertension Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Pulmonary Arterial Hypertension, Total Diagnosed Cases of Pulmonary Arterial Hypertension, Age-specific Cases of Pulmonary Arterial Hypertension, Class-specific Cases of Pulmonary Arterial Hypertension, Gender-specific Cases of Pulmonary Arterial Hypertension, and Subtype-specific Cases of Pulmonary Arterial Hypertension scenario of Pulmonary Arterial Hypertension in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Key Findings

  • The total prevalent cases of PAH in the 7MM were estimated to be approximately 87,713 cases in 2021, which are expected to increase by 2032.
  • According to DelveInsight estimates, in 2021, the total diagnosed prevalent cases of Pulmonary Arterial Hypertension were estimated to be approximately 52,628 in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
  • Among the 7MM, the United States accounted for nearly 58% of the total diagnosed prevalent cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021, which are expected to increase further by 2032.
  • As per DelveInsight analysis, in EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Pulmonary Arterial Hypertension with approximately 5,065 in 2021, while Spain had the lowest diagnosed prevalent population of Pulmonary Arterial Hypertension with approximately 2,826 cases in 2021.
  • In 2021, the diagnosed prevalent population of Pulmonary Arterial Hypertension in Japan was found to be approximately 2,394 cases, which is expected to decrease during the study period of 2019-2032.
  • According to estimates based on DelveInsight's epidemiology model for Pulmonary Arterial Hypertension, the gender distribution of the disease suggests a female predominance across the 7MM, with approximately 7,348 male and 23,193 female cases in the US in 2021.
  • The age-specific cases of PAH in the US in 2021 were approximately 660, 498, 1,191, 2,260, 3,567, 4,716, 5,879, and 11,771 cases of PAH in the age group <18, 18-25, 26-35, 36-45, 46-55, 56-65, 66-75, and >75, respectively, which are expected to increase by 2032.
  • In 2021, in EU4 and the UK, the highest number of subtype-specific cases reported were of idiopathic/heritable PAH, which were approximately 7,720 cases. The cases of drug/toxin induced PAH, connective tissue disease, HIV-related PAH, portopulmonary hypertension, congenital heart disease, and pulmonary veno-occlusive disease were 811, 3,860, 1,327, 1,501, 4,106, and 368, respectively.
  • In 2021, in Japan, there were approximately 205 cases of class I, 1,148 cases of class II, 904 cases of class III, and 137 cases of class IV, which are expected to decrease by 2032.

Pulmonary Arterial Hypertension Epidemiology

The epidemiology segment also provides the Pulmonary Arterial Hypertension epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Pulmonary Arterial Hypertension Drug Chapters

The drug chapter segment of the Pulmonary Arterial Hypertension report encloses a detailed analysis of Pulmonary Arterial Hypertension marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Pulmonary Arterial Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Pulmonary Arterial Hypertension Marketed Drugs

Various therapies are approved for the treatment of PAH across FCs like UPTRAVI (selexipag), REMODULIN (treprostinil) (IV, SC), TYVASO (treprostinil, inhaled), ADEMPAS (riociguat), OPSUMIT (macitentan), ORENITRAM (treprostinil), and others.

UPTRAVI (selexipag): Johnson & Johnson/Nippon Shinyaku

UPTRAVI is a selective prostacyclin receptor agonist structurally distinct from prostacyclin. It is hydrolyzed by carboxylesterase 1 to yield an active metabolite more potent than selexipag. The prostacyclin receptor is one of the five major types of prostanoid receptors (IP, EP, DP, TP, and FP). In contrast to other prostanoid receptors, selexipag and its active metabolite are both selective for the prostacyclin receptor. Activation of the prostacyclin receptor induces vasodilation in pulmonary circulation and inhibits the proliferation of vascular smooth muscle cells, the key factor in PAH pathogenesis. Thus by dilating blood vessels in PAH individuals, selexipag decreases the pressure in the vessels supplying blood to the lungs.

Products detail in the report…

REMODULIN/ TREPROST (treprostinil): United Therapeutics/ Mochida Pharmaceuticals

REMODULIN is a prostacyclin mimetic formulated for SC or IV administration to treat PAH (WHO Group 1) and to diminish associated symptoms with exercise. It is included in patients with NYHA FC II-IV symptoms and etiologies of IPAH, HPAH, PAH associated with CTD, and PAH associated with congenital systemic-to-pulmonary shunts. It is also recommended for patients with PAH requiring transition from epoprostenol, as it diminishes the rate of clinical deterioration. United Therapeutics is currently conducting Phase I studies to develop a new prodrug called RemoPro (treprostinil) to enable SC delivery of treprostinil analog therapy without any site pain that is associated with SC REMODULIN (treprostinil).

Products detail in the report…

TYVASO (treprostinil): United Therapeutics

TYVASO is a drug-device combination therapy comprised of a dry powder formulation of treprostinil and a small, portable dry powder inhaler. It is a single-dose plastic cartridge filled with 1% treprostinil, a prostacyclin mimetic for administration by oral inhalation using the TYVASO DPI inhaler. TYVASO DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza (insulin human) inhalation powder product, which the FDA approved in 2014. DPI device represents a convenient option for the administration of treprostinil therapy. TYVASO was initially approved as an inhalation solution for oral inhalation using the TYVASO Inhalation System, which consisted of Optineb-ir, an ultrasonic, pulsed-delivery device.

Products detail in the report…

List of products to be continued in the report…

Pulmonary Arterial Hypertension Emerging Drugs

The potential drugs expected to launch in the forecast period include Sotatercept (MK-7962) (Merck), ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), seralutinib (GB002) (Gossamer Bio), YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies), TNX-201 (Tenax Therapeutics), and others.

Sotatercept (MK-7962): Merck

Sotatercept is an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein designed to be a selective ligand trap for members of the TGF-beta superfamily to re-balance antiproliferative (BMPRII/Smad1/5/8-mediated) and pro-proliferative (ActRIIA/Smad2/3-mediated) signaling, which is a key molecular driver of PAH. Recently, Merck announced positive results of the Phase III STELLAR trial evaluating the safety and efficacy of Sotatercept as an add-on to stable background therapy for treating PAH (WHO Group 1). Additional Phase III trials evaluating Sotatercept in patients with PAH include ZENITH and HYPERION. Merck is also conducting Phase II trials to assess the safety and efficacy of Sotatercept in children with PAH.

Products detail in the report…

Ralinepag: United Therapeutics

Ralinepag is a novel, oral, selective, and potent prostacyclin receptor agonist being developed by United Therapeutics for treating PAH. In vitro studies indicate that Ralinepag has high binding affinity and selectivity at the human prostacyclin (IP) receptor. United Therapeutics is currently enrolling two Phase III studies of Ralinepag, ADVANCE OUTCOMES, and ADVANCE CAPACITY. Both of these studies are global, multicenter, placebo-controlled trials of patients on approved oral background PAH therapies.

Products detail in the report…

RT234 (vardenafil inhalation powder): Respira Therapeutics

RT234 is a first-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in PAH patients (Group 1 in the WHO's classification of PH indications). RT234 is a drug-device combination of a capsule and the novel axial oscillating sphere (AOS) dry powder inhaler. Vardenafil is a dry powder; the inhaler is specifically designed to deliver this powdered drug to the lungs. Respira intends to pursue additional indications for RT234 in other WHO PH patient groups and is currently conducting Phase IIb trials (VIPAH-PRN 2B) to treat PAH.

Products detailed in the report…

Seralutinib (GB002) (Gossamer Bio)

Seralutinib is an inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor in development for the treatment of PAH. Seralutinib targets PDGFRa/B, CSF1R, and c-KIT and upregulates BMPR2 protein expression; these pathways play important roles in PAH. It significantly reduces the right ventricular systolic pressure and mean pulmonary artery pressure. Recently, Gossamer Bio announced the topline results from the Phase II TORREY study, favoring seralutinib with enhanced effects in patients with more severe disease at baseline. Gossamer Bio had commenced investment in operational activities to enable the commencement of a registrational Phase III clinical program by the third quarter of 2023.

Products detailed in the report…

List of products to be continued in the report…

Pulmonary Arterial Hypertension Market Outlook

The current mainstay therapies to treat PAH act to dilate the pulmonary vasculature, decreasing pulmonary vascular resistance and secondarily improving right ventricular function, thereby improving functional capacity. The overall treatment goal is to improve survival, quality of life, exercise capacity, symptom burden, and clinical worsening, with risk stratification tools increasingly used to guide therapy and improve each of these elements. Current treatment recommendations weigh the use of multiple factors, including WHO FC, exercise ability, lab indices, and hemodynamic and echocardiographic variables to establish the overall severity of the disease and guide the intensity of therapy. Initial therapy choices and subsequent therapy changes are determined to achieve a low-risk category that helps improve overall survival and functional status in PAH.

The four drug classes (PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analog, and agonists) widely used for treating target three major signaling pathways, prostacyclin, endothelin, and nitric oxide, are responsible for PAH. The marketed therapies approved for the treatment of PAH across various WHO Functional Classes (FC) include Johnson & Johnson/Nippon Shinyaku's UPTRAVI (selexipag) and OPSUMIT (macitentan), United Therapeutics' REMODULIN (treprostinil) (IV, SC), TYVASO (treprostinil, Inhaled), and ORENITRAM (treprostinil), Bayer/Merck's ADEMPAS (riociguat). Other therapies which were approved but have their generics in the market include REVATIO (sildenafil), ADCIRCA (tadalafil), LETAIRIS/ VOLIBRIS (ambrisentan), VENTAVIS (iloprost), TRACLEER (Bosentan), BERAPROST (TRK-100), and VELETRI (epoprostenol).

Recently a combination therapy of LETAIRIS/ VOLIBRIS (ambrisentan) and ADCIRCA (tadalafil) also received approval. Most of these therapies are approved for adults except sildenafil, though trials are ongoing in the pediatric population for UPTRAVI, ADEMPAS, and OPSUMIT. Janssen Pharmaceuticals is also developing OPSUMIT with tadalafil as a fixed-dose combination formulation.

None of these drugs are curative and have side effects associated with their long-term use. The market has a thirst for therapies that address the shortcomings associated with the current treatment regime. Newer treatments with a novel mechanism of action are expected to enter the market and change the treatment and market regime.

According to DelveInsight, the overall dynamics of the Pulmonary Arterial Hypertension market is anticipated to change in the coming years owing to the expected launch of emerging therapies.

Key Findings

  • The market size of Pulmonary Arterial Hypertension in the seven major markets was approximately USD 4,871.0 million in 2021, which is further expected to increase by 2032.
  • The market size in the 7MM will increase at a CAGR of 3.6% due to increasing awareness of the disease.
  • Among the 7MM countries, the US accounted for the highest market size of Pulmonary Arterial Hypertension with approximately USD 3,848.1 million in 2021 which is likely to increase by 2032.
  • Among EU4 and the United Kingdom, Germany accounted for approximately USD 211.2 million in 2021, followed by France with approximately USD 169.1 million in the respective year, while Spain accounted for the lowest market with approximately USD 117.0 million in 2021.
  • Japan accounted for approximately USD 243.0 million in 2021, which is expected to increase by 2032.

The United States Market Outlook

This section provides the total Pulmonary Arterial Hypertension market size and market size by therapies (therapeutic and prophylactic) in the United States.

EU4 and the United Kingdom Market Outlook

The total Pulmonary Arterial Hypertension market size and market size by therapies (therapeutic and prophylactic) in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Pulmonary Arterial Hypertension market size and market size by therapies (therapeutic and prophylactic) in Japan are provided.

Pulmonary Arterial Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Pulmonary Arterial Hypertension market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Pulmonary Arterial Hypertension emerging therapies.

Reimbursement Scenario in Pulmonary Arterial Hypertension

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Pulmonary Arterial Hypertension market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers a descriptive overview of Pulmonary Arterial Hypertension, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Pulmonary Arterial Hypertension epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Arterial Hypertension is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Pulmonary Arterial Hypertension market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Pulmonary Arterial Hypertension market.

Report Highlights:

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Pulmonary Arterial Hypertension market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Pulmonary Arterial Hypertension. The launch of emerging therapies (therapeutic and prophylactic) will significantly impact the Pulmonary Arterial Hypertension market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Pulmonary Arterial Hypertension Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pulmonary Arterial Hypertension Pipeline Analysis
  • Pulmonary Arterial Hypertension Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies (therapeutic and prophylactic)

Pulmonary Arterial Hypertension Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage
  • Pulmonary Arterial Hypertension Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Pulmonary Arterial Hypertension Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Pulmonary Arterial Hypertension market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Pulmonary Arterial Hypertension total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Pulmonary Arterial Hypertension market size during the forecast period (2022-2032)?
  • At what CAGR, the Pulmonary Arterial Hypertension market is expected to grow at the 7MM level during the forecast period (2022-2032)?
  • What would be the Pulmonary Arterial Hypertension market outlook across the 7MM during the forecast period (2022-2032)?
  • What would be the Pulmonary Arterial Hypertension market growth till 2032 and what will be the resultant market size in the year 2032?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Pulmonary Arterial Hypertension?
  • What is the historical Pulmonary Arterial Hypertension patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • What would be the forecasted patient pool of Pulmonary Arterial Hypertension at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Pulmonary Arterial Hypertension?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Pulmonary Arterial Hypertension during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Pulmonary Arterial Hypertension along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Pulmonary Arterial Hypertension in the US and Europe?
  • What are the Pulmonary Arterial Hypertension marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Pulmonary Arterial Hypertension?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Pulmonary Arterial Hypertension?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Pulmonary Arterial Hypertension therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
  • What are the key designations that have been granted for the emerging therapies for Pulmonary Arterial Hypertension?
  • What is the 7MM historical and forecasted market for Pulmonary Arterial Hypertension?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving Pulmonary Arterial Hypertension.
  • To understand the future market competition in the Pulmonary Arterial Hypertension market.
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Pulmonary Arterial Hypertension market.
  • To understand the future market competition in the Pulmonary Arterial Hypertension market.

Table of Contents

1. Key Insights

2. Report Introduction

3. PAH Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of PAH in 2019
  • 3.2. Market Share (%) Distribution of PAH in 2032

4. Methodology of PAH Epidemiology and Market

5. Executive Summary of PAH

6. Key Events

7. Disease Background and Overview

  • 7.1. Introduction to PAH
  • 7.2. Signs and Symptoms
  • 7.3. Classification of PAH
    • 7.3.1. WHO classification
    • 7.3.2. Functional Classification of PAH
  • 7.4. Etiology
  • 7.5. Risk factors
  • 7.6. Pathophysiology
    • 7.6.1. Nitric oxide (NO) pathway
    • 7.6.2. Prostacyclin-thromboxane A2 pathway
    • 7.6.3. Endothelin-1 pathway
  • 7.7. Diagnosis
  • 7.8. Management and Treatment
  • 7.9. Treatment Guidelines
    • 7.9.1. American College of Chest Physicians (CHEST) Guidelines
    • 7.9.2. European Society of Cardiology (ESC)/ the European Respiratory Society (ERS) Guidelines for the Treatment of Pulmonary Hypertension

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Assumptions and Rationale: The 7MM
    • 8.2.1. Total Prevalent Cases of PAH
    • 8.2.2. Total Diagnosed Cases of PAH
    • 8.2.3. Age-specific cases of PAH
    • 8.2.4. Class-specific Cases of PAH
    • 8.2.5. Gender-specific cases of PAH
    • 8.2.6. Subtype-specific cases of PAH
  • 8.3. Total Prevalent Cases of PAH in the 7MM
  • 8.4. Total Diagnosed Cases of PAH in the 7MM
  • 8.5. The US
    • 8.5.1. Total Prevalent Cases of PAH in the US
    • 8.5.2. Total Diagnosed Cases of PAH in the US
    • 8.5.3. Age-specific Cases of PAH in the US
    • 8.5.4. Class-specific Cases of PAH in the US
    • 8.5.5. Gender-specific Cases of PAH in the US
    • 8.5.6. Subtype-specific Cases of PAH in the US
  • 8.6. EU4 and the UK
    • 8.6.1. Total Prevalent Cases of PAH in EU4 and the UK
    • 8.6.2. Total Diagnosed Cases of PAH in EU4 and the UK
    • 8.6.3. Age-specific Cases of PAH in EU4 and the UK
    • 8.6.4. Class-specific Cases of PAH in EU4 and the UK
    • 8.6.5. Gender-specific Cases of PAH in EU4 and the UK
    • 8.6.6. Subtype-specific Cases of PAH in EU4 and the UK
    • 8.6.7. Germany
      • 8.6.7.1. Total Prevalent Cases of PAH in Germany
      • 8.6.7.2. Total Diagnosed Cases of PAH in Germany
      • 8.6.7.3. Age-specific Cases of PAH in Germany
      • 8.6.7.4. Class-specific Cases of PAH in Germany
      • 8.6.7.5. Gender-specific Cases of PAH in Germany
      • 8.6.7.6. Subtype-specific Cases of PAH in Germany
    • 8.6.8. France
      • 8.6.8.1. Total Prevalent Cases of PAH in France
      • 8.6.8.2. Total Diagnosed Cases of PAH in France
      • 8.6.8.3. Age-specific Cases of PAH in France
      • 8.6.8.4. Class-specific Cases of PAH in France
      • 8.6.8.5. Gender-specific Cases of PAH in France
      • 8.6.8.6. Subtype-specific Cases of PAH in France
    • 8.6.9. Italy
      • 8.6.9.1. Total Prevalent Cases of PAH in Italy
      • 8.6.9.2. Total Diagnosed Cases of PAH in Italy
      • 8.6.9.3. Age-specific Cases of PAH in Italy
      • 8.6.9.4. Class-specific Cases of PAH in Italy
      • 8.6.9.5. Gender-specific Cases of PAH in Italy
      • 8.6.9.6. Subtype-specific Cases of PAH in Italy
    • 8.6.10. Spain
      • 8.6.10.1. Total Prevalent Cases of PAH in Spain
      • 8.6.10.2. Total Diagnosed Cases of PAH in Spain
      • 8.6.10.3. Age-specific Cases of PAH in Spain
      • 8.6.10.4. Class-specific Cases of PAH in Spain
      • 8.6.10.5. Gender-specific Cases of PAH in Spain
      • 8.6.10.6. Subtype-specific Cases of PAH in Spain
    • 8.6.11. The UK
      • 8.6.11.1. Total Prevalent Cases of PAH in the UK
      • 8.6.11.2. Total Diagnosed Cases of PAH in the UK
      • 8.6.11.3. Age-specific Cases of PAH in the UK
      • 8.6.11.4. Class-specific Cases of PAH in the UK
      • 8.6.11.5. Gender-specific Cases of PAH in the UK
      • 8.6.11.6. Subtype-specific Cases of PAH in the UK
  • 8.7. Japan
    • 8.7.1. Total Prevalent Cases of PAH in Japan
    • 8.7.2. Total Diagnosed Cases of PAH in Japan
    • 8.7.3. Age-specific Cases of PAH in Japan
    • 8.7.4. Class-specific Cases of PAH in Japan
    • 8.7.5. Gender-specific Cases of PAH in Japan
    • 8.7.6. Subtype-specific Cases of PAH in Japan

9. Patient Journey

10. Marketed Drugs

  • 10.1. Key Cross Competition
  • 10.2. UPTRAVI (selexipag): Johnson & Johnson/Nippon Shinyaku
    • 10.2.1. Product description
    • 10.2.2. Regulatory milestone
    • 10.2.3. Other development activities
    • 10.2.4. Clinical development
    • 10.2.5. Clinical trial information
    • 10.2.6. Safety and efficacy
    • 10.2.7. Product profile
  • 10.3. REMODULIN/ TREPROST (treprostinil): United Therapeutics/ Mochida Pharmaceutical
    • 10.3.1. Product description
    • 10.3.2. Regulatory milestone
    • 10.3.3. Other development activities
    • 10.3.4. Safety and efficacy
    • 10.3.5. Product profile
  • 10.4. TYVASO (treprostinil): United Therapeutics
    • 10.4.1. Product description
    • 10.4.2. Regulatory milestone
    • 10.4.3. Other development activities
    • 10.4.4. Clinical trial information
    • 10.4.5. Safety and efficacy
    • 10.4.6. Product profile
  • 10.5. ORENITRAM (treprostinil): United Therapeutics
    • 10.5.1. Drug description
    • 10.5.2. Regulatory milestone
    • 10.5.3. Other development activities
    • 10.5.4. Clinical trial information
    • 10.5.5. Safety and efficacy
    • 10.5.6. Product profile
  • 10.6. ADEMPAS (riociguat): Bayer/Merck
    • 10.6.1. Product description
    • 10.6.2. Regulatory milestone
    • 10.6.3. Other development activities
    • 10.6.4. Clinical trial information
    • 10.6.5. Safety and efficacy
    • 10.6.6. Product profile
  • 10.7. OPSUMIT (macitentan): Johnson & Johnson/Nippon Shinyaku
    • 10.7.1. Drug description
    • 10.7.2. Regulatory milestone
    • 10.7.3. Other development activities
    • 10.7.4. Clinical development
    • 10.7.5. Clinical trial information
    • 10.7.6. Safety and efficacy
    • 10.7.7. Product profile

11. Emerging Drugs

  • 11.1. Key Cross Competition
  • 11.2. Sotatercept (MK-7962): Merck
    • 11.2.1. Product description
    • 11.2.2. Other development activities
    • 11.2.3. Clinical development
    • 11.2.4. Clinical trial information
    • 11.2.5. Safety and efficacy
    • 11.2.6. Product profile
    • 11.2.7. Analysts' views
  • 11.3. Ralinepag: United Therapeutics
    • 11.3.1. Product description
    • 11.3.2. Other development activities
    • 11.3.3. Clinical development
    • 11.3.4. Clinical trial information
    • 11.3.5. Safety and efficacy
    • 11.3.6. Product profile
    • 11.3.7. Analysts' views
  • 11.4. YUTREPIA (treprostinil): Liquida Technologies
    • 11.4.1. Product description
    • 11.4.2. Other development activities
    • 11.4.3. Clinical development
    • 11.4.4. Clinical trial information
    • 11.4.5. Safety and efficacy
    • 11.4.6. Product profile
    • 11.4.7. Analysts' views
  • 11.5. TNX-201: Tenax Therapeutics
    • 11.5.1. Product description
    • 11.5.2. Other development activities
    • 11.5.3. Clinical development
    • 11.5.4. Clinical trial information
    • 11.5.5. Safety and efficacy
    • 11.5.6. Product profile
    • 11.5.7. Analysts' views
  • 11.6. RT234 (vardenafil inhalation powder): Respira Therapeutics
    • 11.6.1. Product description
    • 11.6.2. Other development activities
    • 11.6.3. Clinical development
    • 11.6.4. Clinical trial information
    • 11.6.5. Safety and efficacy
    • 11.6.6. Product profile
    • 11.6.7. Analysts' views
  • 11.7. Seralutinib (GB002): Gossamer Bio
    • 11.7.1. Product description
    • 11.7.2. Other development activities
    • 11.7.3. Clinical development
    • 11.7.4. Clinical trial information
    • 11.7.5. Safety and efficacy
    • 11.7.6. Product profile
    • 11.7.7. Analysts' views
  • 11.8. L606 (liposomal treprostinil): Pharmosa Biopharma
    • 11.8.1. Product description
    • 11.8.2. Clinical development
    • 11.8.3. Clinical trial information
    • 11.8.4. Safety and efficacy
    • 11.8.5. Product profile
    • 11.8.6. Analysts' views
  • 11.9. MK-5475: Merck Sharp & Dohme
    • 11.9.1. Product description
    • 11.9.2. Clinical development
    • 11.9.3. Clinical trial information
    • 11.9.4. Safety and efficacy
    • 11.9.5. Product profile
  • 11.10. AV-101: Aerovate Therapeutics
    • 11.10.1. Product description
    • 11.10.2. Other development activities
    • 11.10.3. Clinical development
    • 11.10.4. Clinical trial information
    • 11.10.5. Safety and efficacy
    • 11.10.6. Product profile
  • 11.11. Treprostinil Palmitil: Insmed
    • 11.11.1. Product description
    • 11.11.2. Other development activities
    • 11.11.3. Clinical development
    • 11.11.4. Clinical trial information
    • 11.11.5. Safety and Efficacy
    • 11.11.6. Product profile
  • 11.12. LTP001: Novartis
    • 11.12.1. Product description
    • 11.12.2. Clinical development
    • 11.12.3. Clinical trial information
    • 11.12.4. Product profile
    • 11.12.5. Analysts' views
  • 11.13. Oral Ifetroban: Cumberland Pharmaceuticals
    • 11.13.1. Product description
    • 11.13.2. Other development activities
    • 11.13.3. Clinical development
    • 11.13.4. Clinical trial information
    • 11.13.5. Product profile
    • 11.13.6. Analysts' views
  • 11.14. Rodatristat Ethyl: Enzyvant Therapeutics
    • 11.14.1. Product description
    • 11.14.2. Other development activities
    • 11.14.3. Clinical development
    • 11.14.4. Clinical trial information
    • 11.14.5. Safety and efficacy
    • 11.14.6. Product profile
    • 11.14.7. Analysts' views
  • 11.15. CS1: Cereno Scientific
    • 11.15.1. Product description
    • 11.15.2. Other development activities
    • 11.15.3. Clinical development
    • 11.15.4. Clinical trial information
    • 11.15.5. Product profile
  • 11.16. Olaparib: AstraZeneca
    • 11.16.1. Product description
    • 11.16.2. Clinical development
    • 11.16.3. Clinical trial information
    • 11.16.4. Product profile
    • 11.16.5. Analysts' views
  • 11.17. PB1046: PhaseBio Pharmaceutical
    • 11.17.1. Product description
    • 11.17.2. Other development activities
    • 11.17.3. Clinical development
    • 11.17.4. Clinical trial information
    • 11.17.5. Product profile
    • 11.17.6. Analysts' views

12. PAH: Market Analysis

  • 12.1. Key Findings
  • 12.2. Key Market Forecast Assumptions
  • 12.3. Market Outlook
  • 12.4. Attribute Analysis
  • 12.5. Market Size of PAH in the 7MM
  • 12.6. Market Size of PAH by Therapies in the 7MM
  • 12.7. Market Size of PAH in the US
    • 12.7.1. Total market size of PAH
    • 12.7.2. Market size of PAH by therapies
  • 12.8. Market Size of PAH in EU4 and the UK
    • 12.8.1. Total market size of PAH
    • 12.8.2. Market size of PAH by therapies
    • 12.8.3. Germany
      • 12.8.3.1. Total market size of PAH
      • 12.8.3.2. Market size of PAH by therapies
    • 12.8.4. France
      • 12.8.4.1. Total market size of PAH
      • 12.8.4.2. Market size of PAH by therapies
    • 12.8.5. Italy
      • 12.8.5.1. Total market size of PAH
      • 12.8.5.2. Market size of PAH by therapies
    • 12.8.6. Spain
      • 12.8.6.1. Total market size of PAH
      • 12.8.6.2. Market size of PAH by therapies
    • 12.8.7. The UK
      • 12.8.7.1. Total market size of PAH
      • 12.8.7.2. Market size of PAH by therapies
  • 12.9. Market Size of PAH in Japan
    • 12.9.1. Total market size of PAH
    • 12.9.2. Market size of PAH by therapies

13 Key Opinion Leaders' Views

14 SWOT Analysis

15 Unmet Need

16 Market Access and Reimbursement

  • 16.1. The United States
    • 16.1.1. Center for Medicare & Medicaid Services (CMS)
  • 16.2. EU4 and the UK
    • 16.2.1. Germany
    • 16.2.2. France
    • 16.2.3. Italy
    • 16.2.4. Spain
    • 16.2.5. The United Kingdom
  • 16.3. Japan
    • 16.3.1. MHLW

17. Appendix

  • 17.1. Bibliography
  • 17.2. Acronyms and Abbreviations
  • 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight